FDA Research Opportunity, Bacteriophage Therapy as a Preventative of Menstrual Toxic Shock Syndrome (mTSS) — U.S. Food and Drug Administration (FDA) – National Center for Toxicological Research

FDA-funded research fellowship developing bacteriophage and endolysin therapies to prevent menstrual toxic shock syndrome caused by Staphylococcus aureus through microbiome-informed experimental and bioinformatic approaches.